CpdA

CpdA (Compound A) is a potent and selective small-molecule agonist of the Free Fatty-Acid Receptor 4 (FFA4), also known as GPR120. It is widely utilized as a pharmacological tool in metabolic research to investigate the therapeutic potential of FFA4 in treating type 2 diabetes and obesity. CpdA has been shown to potentiate glucose-stimulated insulin secretion (GSIS) through distinct species-specific mechanisms: in rodent models, it acts indirectly by inhibiting somatostatin release from pancreatic delta cells via Gαz coupling, whereas in human islets, it appears to act directly on beta cells. Additionally, CpdA exerts anti-inflammatory effects in macrophages and improves insulin sensitivity in adipose tissue. While it is a significant lead compound in the development of GPR120-targeted therapies, it is currently primarily used in preclinical and laboratory research.

Other names

GPR120 agonist Compound AGPR-120 agonist Compound AGPR 120 agonist Compound AFFA4 agonist Compound AFFA-4 agonist Compound AFFA 4 agonist Compound A